50 employees
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
2016
$64M
from 5 investors over 5 rounds
Eidos Therapeutics raised $64M on April 5, 2018
Investors: Aisling Capital, BridgeBio, Viking Global Investors, RA Capital Management, L.P. and Perceptive Advisors